
ARTICLE IN PRESS

Gynecologic Oncology xxx (2018) xxx-xxx



Contents lists available at ScienceDirect

Gynecologic Oncology



journal homepage: www.elsevier.com/locate/ygyno



Impact of hospital volume on racial disparities and outcomes for endometrial cancer^{*}

Ama Buskwofie^a, Yongmei Huang^a, Ana I. Tergas^{a,c,d,e}, June Y. Hou^{a,d,e}, Cande V. Ananth^{a,c}, Alfred I. Neugut^{b,c,d,e}, Dawn L. Hershman^{b,c,d,e}, Jason D. Wright^{a,d,e,*}

^a Department of Obstetrics and Gynecology, Columbia University College of Physicians and Surgeons, United States

^b Department of Medicine, Columbia University College of Physicians and Surgeons, United States

^c Department of Epidemiology, Joseph L. Mailman School of Public Health, Columbia University, United States

^d Herbert Irving Comprehensive Cancer Center, Columbia University College of Physicians and Surgeons, United States

^e New York Presbyterian Hospital, United States

HIGHLIGHTS

• Black race is an independent predictor of mortality for women with endometrial cancer.

• Black women with endometrial cancer are more likely to receive treatment at a high volume hospital.

• The impact of race on mortality is mitigated, albeit not eliminated, by increasing hospital volume.

ARTICLE INFO

Article history: Received 26 January 2018 Received in revised form 21 February 2018 Accepted 24 February 2018 Available online xxxx

Keywords: Endometrial cancer Uterine cancer Disparities Black Hysterectomy

ABSTRACT

Objective. Little is known about the influence of hospital procedural volume on racial disparities for uterine cancer. We examined whether the magnitude of the survival differential between black and white women varied based on hospital procedural volume for endometrial cancer.

Methods. We utilized the National Cancer Data Base to examine women with endometrial cancer from 1998 to 2012. Annualized hospital procedural volume was calculated and hospitals grouped into volume-based quartiles. Multivariable models were developed to examine differences in two and five-year survival between black and white women across the hospital volume categories. Patients were classified as early or advanced stage and as type I (low grade, endometrioid) or type II (high grade endometrioid, other histologies) cancers.

Results. We identified 243,422 (75.0%) white and 27,764 (8.6%) black women treated at 1059 hospitals. Regardless of hospital volume, black women had decreased survival. For each tumor class, the absolute difference in adjusted two-year survival between black and white women decreased with increasing hospital volume. For example, for women with early-stage, type I tumors, the adjusted two-year survival differential between blacks and whites was -1.4% (95%CI, -2.4 to -0.5%) at low volume centers and decreased to -0.5% (95%CI, -0.9 to 0%) at high-volume hospitals (P < 0.0001). For advanced stage, type I tumors, the adjusted survival differential decreased from -12.4% (95%CI, -24.0 to -0.9%) to 1.2% (95%CI, -2.9 to 5.3%) at high volume hospitals (P < 0.0001).

Conclusion. Black race is an independent predictor of mortality. The impact of race on mortality is mitigated, albeit not eliminated, by increasing hospital volume.

© 2018 Published by Elsevier Inc.

1. Introduction

E-mail address: jw2459@columbia.edu (J.D. Wright).

Endometrial cancer is associated with a favorable prognosis overall, however, significant disparities exist in outcomes between black and white women. Compared to white women, black woman are nearly twice as likely to die from their disease (7.9 per 100,000 vs 4.1 per 100,000) [1,2]. The 5-year relative survival rate for white women with uterine cancer is 84%, compared to 62% for black women [3]. Additionally,

https://doi.org/10.1016/j.ygyno.2018.02.019 0090-8258/© 2018 Published by Elsevier Inc.

Please cite this article as: A. Buskwofie, et al., Impact of hospital volume on racial disparities and outcomes for endometrial cancer, Gynecol Oncol (2018), https://doi.org/10.1016/j.ygyno.2018.02.019

 $[\]star$ Dr. Wright (NCI R01CA169121-01A1) and Dr. Hershman (NCI R01 CA166084) are recipients of grants from the National Cancer Institute. Dr. Hershman is the recipient of a grant from the Breast Cancer Research Foundation/Conquer Cancer Foundation.

^{*} Corresponding author at: Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Columbia University College of Physicians and Surgeons, 161 Fort Washington Ave, 8th Floor, New York, NY 10032, United States.

2

ARTICLE IN PRESS

A. Buskwofie et al. / Gynecologic Oncology xxx (2018) xxx-xxx

Table 1

Clinical and characteristics of study cohort stratified by hospital volume quartile.

	Total		Hospital volume ≤ 10		Hospital volume 10.01–20		Hospital volume 20.01–60		Hospital volume > 60		P-value
	п	%	п	%	n	%	п	%	п	%	
Number of patients	324,502	(100.0)	40,639	(12.5)	48,981	(15.1)	149,512	(46.1)	85,370	(26.3)	
Number of hospitals	1059	(100.0)	444	(41.9)	246	(23.2)	299	(28.2)	70	(6.6)	0.0001
Age of diagnosis	11 2 40	(25)	1201	(2.4)	1700	(25)	5250	(25)	2001	(25)	<0.0001
<40 40–49	11,348 35,148	(3.5) (10.8)	1391 4752	(3.4)	1706 5500	(3.5) (11.2)	5250 15,980	(3.5) (10.7)	3001 8916	(3.5) (10.4)	
50–59	94,979	(29.3)	4752	(11.7) (28.0)	14,186	(11.2) (29)	43,874	(29.3)	25,536	(29.9)	
60-69	94,979 99,200	(30.6)	11,383	(28.0)	14,180	(29)	45,930	(30.7)	26,860	(31.5)	
70–79	58,753	(18.1)	7735	(19.0)	9080	(18.5)	27,032	(18.1)	14,906	(17.5)	
≥80	25,074	(7.7)	3548	(8.7)	3929	(8.0)	11,446	(7.7)	6151	(7.2)	
Race	- , -					()	,				< 0.0001
White	243,422	(75.0)	32,349	(79.6)	37,385	(76.3)	108,816	(72.8)	64,872	(76.0)	
Black	27,764	(8.6)	2850	(7.0)	3936	(8.0)	13,956	(9.3)	7022	(8.2)	
Hispanic	16,266	(5.0)	1618	(4.0)	2650	(5.4)	9010	(6.0)	2988	(3.5)	
Other	9918	(3.1)	986	(2.4)	1358	(2.8)	4576	(3.1)	2998	(3.5)	
Unknown	27,132	(8.4)	2836	(7.0)	3652	(7.5)	13,154	(8.8)	7490	(8.8)	
Insurance											< 0.0001
Private insurance	167,967	(51.8)	20,140	(49.6)	25,607	(52.3)	77,976	(52.2)	44,244	(51.8)	
Medicaid	14,481	(4.5)	1880	(4.6)	2238	(4.6)	6631	(4.4)	3732	(4.4)	
Medicare	119,474	(36.8)	16,016	(39.4)	17,961	(36.7)	54,813	(36.7)	30,684	(35.9)	
Not insured	11,919	(3.7)	1429	(3.5)	1955	(4)	5712	(3.8)	2823	(3.3)	
Other government	2637	(0.8)	313	(0.8)	313	(0.6)	1336	(0.9)	675	(0.8)	
Unknown Madian hannahald in carry	8024	(2.5)	861	(2.1)	907	(1.9)	3044	(2.0)	3212	(3.8)	.0.0001
Median household income	20.405	(12.1)	5000	(40.5)	5 400	(44.4)	10.040	(40.5)	10.000		<0.0001
<\$30,000	39,185	(12.1)	5088	(12.5)	5428	(11.1)	18,649	(12.5)	10,020	(11.7)	
\$30,000-\$35,999	54,517	(16.8)	8081	(19.9)	8259	(16.9)	24,049	(16.1)	14,128	(16.5)	
\$36,000-\$45,999	87,606	(27.0)	11,660	(28.7)	13,885	(28.3)	38,973	(26.1)	23,088	(27.0)	
\$46,000 +	129,889	(40.0)	14,191	(34.9)	19,319	(39.4)	61,864	(41.4)	34,515	(40.4)	
Unknown Patient's residence area	13,305	(4.1)	1619	(4.0)	2090	(4.3)	5977	(4.0)	3619	(4.2)	<0.0001
Metropolitan	256,437	(79.0)	29,392	(72.3)	39,949	(81.6)	122,896	(82.2)	64,200	(75.2)	<0.0001
Urban	48,323	(14.9)	29,392 8456	(72.3) (20.8)	6243	(12.7)	122,890	(12.5)	14,881	(17.4)	
Rural	6329	(14.5) (2.0)	1052	(2.6)	768	(12.7)	2642	(12.3)	1867	(2.2)	
Unknown	13,413	(4.1)	1739	(4.3)	2021	(4.1)	5231	(3.5)	4422	(5.2)	
Comorbidity score	13,113	()	1755	(1.5)	2021	(1.1)	5251	(3.5)	1 122	(3.2)	< 0.0001
0	185,128	(57.0)	20,936	(51.5)	27,914	(57.0)	86,309	(57.7)	49,969	(58.5)	-0.0001
1	48,521	(15.0)	4706	(11.6)	6305	(12.9)	23,312	(15.6)	14,198	(16.6)	
≥2	10,728	(3.3)	1025	(2.5)	1255	(2.6)	5313	(3.6)	3135	(3.7)	
Unknown	80,125	(24.7)	13,972	(34.4)	13,507	(27.6)	34,578	(23.1)	18,068	(21.2)	
Year of diagnosis	,				- ,		,		.,		< 0.0001
1998-2002	80,125	(24.7)	13,972	(34.4)	13,507	(27.6)	34,578	(23.1)	18,068	(21.2)	
2003-2007	105,551	(32.5)	14,067	(34.6)	16,060	(32.8)	47,734	(31.9)	27,690	(32.4)	
2008-2012	138,826	(42.8)	12,600	(31.0)	19,414	(60.4)	67,200	(45.0)	39,612	(46.4)	
Facility location											
Eastern	74,469	(22.9)	8811	(21.7)	12,252	(25.0)	30,539	(20.4)	22,867	(26.8)	
South	84,459	(26.0)	8575	(21.1)	12,200	(24.9)	38,392	(25.7)	25,292	(29.6)	
Midwest	111,795	(34.5)	16,537	(40.7)	15,543	(31.7)	51,011	(34.1)	28,704	(33.6)	
West	53,779	(16.6)	6716	(16.5)	8986	(18.3)	29,570	(19.8)	8507	(10.0)	
Facility type											< 0.0001
Community cancer program	18,093	(5.6)	13,759	(33.9)	3328	(6.8)	649	(0.4)	357	(0.4)	
Comprehensive community cancer program	172,627	(53.2)	25,308	(62.3)	37,133	(75.8)	81,466	(54.5)	28,720	(33.6)	
Academic program	133,230	(41.1)	1572	(3.9)	8520	(17.4)	67,397	(45.1)	55,741	(65.3)	
Other	552	(0.2)	0	(0.0)	0	(0.0)	0	(0.0)	552	(0.6)	-0.0001
Histology	200 000	(61.0)	22.051	(50.2)	20.071	(50.0)	04.000	((2) ())	E 4 0 7 0	(((4.2))	<0.0001
Endometrioid	200,698	(61.8)	22,851	(56.2)	28,871	(58.9)	94,098	(62.9)	54,878	(64.3)	
Serous	16,990	(5.2)	1604	(3.9)	2255	(4.6)	8200	(5.5)	4931	(5.8)	
Carcinosarcoma	14,771	(4.6)	1554	(3.8)	2042	(4.2)	6993 5026	(4.7)	4182	(4.9)	
Sarcoma Clear cell	12,992 4251	(4.0)	1765	(4.3)	2002 583	(4.1)	5926 2012	(4)	3299 1222	(3.9)	
Other	4251 74,800	(1.3)	434 12,431	(1.1) (30.6)	583 13,228	(1.2) (27.0)	2012 32,283	(1.3)	1222 16,858	(1.4) (19.8)	
Stage	74,000	(23.0)	12,431	(0.0.)	13,220	(27.0)	52,205	(21.6)	10,000	(19.0)	< 0.0001
IA	145,442	(44.8)	16,471	(40.5)	20,485	(41.8)	67,624	(45.2)	40,862	(47.9)	~0.0001
IB	145,442 35,439	(44.8) (10.9)	4690	(40.5) (11.5)	20,485 5453	(41.8)	16,496	(43.2)	40,862 8800	(10.3)	
I NOS	12,871	(10.9) (4.0)	1968	(4.8)	2365	(4.8)	5713	(3.8)	2825	(3.3)	
II	19,583	(6.0)	2456	(6.0)	2986	(6.1)	9164	(6.1)	4977	(5.8)	
III	25,256	(7.8)	2712	(6.7)	3528	(7.2)	11,919	(8.0)	7097	(8.3)	
IV	12,655	(3.9)	1290	(3.2)	1711	(3.5)	5971	(4.0)	3683	(4.3)	
Unknown	73,256	(22.6)	11,052	(27.2)	12,453	(25.4)	32,625	(21.8)	17,126	(20.1)	
Grade	,		,	,,	,	· · · · · /	,	, /	,	、 ···-/	< 0.0001
Well	127,371	(39.3)	17,439	(42.9)	20,365	(41.6)	57,830	(38.7)	31,737	(37.2)	
Moderate	88,910	(27.4)	11,331	(27.9)	13,160	(26.9)	40,887	(27.3)	23,532	(27.6)	
Poorly	71,141	(21.9)	7693	(18.9)	9908	(20.2)	33,465	(22.4)	20,075	(23.5)	
Unknown	37,080	(11.4)	4176	(10.3)	5548	(11.3)	17,330	(11.6)	10,026	(11.7)	

Please cite this article as: A. Buskwofie, et al., Impact of hospital volume on racial disparities and outcomes for endometrial cancer, Gynecol Oncol (2018), https://doi.org/10.1016/j.ygyno.2018.02.019

Download English Version:

https://daneshyari.com/en/article/8780299

Download Persian Version:

https://daneshyari.com/article/8780299

Daneshyari.com